Contact Us
Drug Search Results
More Filters [+]

LML-134

Alternative Names: lml-134, lml134, lml 134
Latest Update: 2019-02-15
Latest Update Note: Clinical Trial Update

Product Description

a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

Mechanisms of Action: H3 Inverse Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LML-134

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sleep Disorders, Circadian Rhythm

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CLML134X2201

P2

Terminated

Sleep Disorders, Circadian Rhythm

2018-08-30

LML134

P1

Completed

Healthy Volunteers

2016-02-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions